Dong-A Pharm's Stillen witnessing successful launching in market

Dong-A Pharm said that its own new anti-ulcerant drug Stillen derived from natural substances has shown brisk sales of 7.0 billion won since the first launching on December of last year, thanks to superior efficacy and intensive marketing in the domestic market where Korean-type natural drugs cannot be viable amid deep distrust on their efficacy.

The company noted that Stillen's sales are ex...